12-May-2026
Canaccord Genuity Keeps Their Buy Rating on Enovis (ENOV)
TipRanks (Mon, 11-May 7:28 AM ET)
Enovis Earnings Call Highlights Recon Strength, Caution
TipRanks (Fri, 8-May 9:37 PM ET)
TipRanks (Fri, 8-May 2:12 PM ET)
TipRanks (Fri, 8-May 1:31 PM ET)
TipRanks (Fri, 8-May 7:30 AM ET)
Enovis Announces First Quarter 2026 Results
Globe Newswire (Thu, 7-May 6:01 AM ET)
Business Wire (Fri, 1-May 1:15 PM ET)
Enovis to Host First Quarter 2026 Results Conference Call on May 7th
Globe Newswire (Fri, 10-Apr 8:00 AM ET)
Update: Enovis Announces Fourth Quarter and Full Year 2025 Results
Globe Newswire (Thu, 26-Feb 6:33 AM ET)
Enovis Announces Fourth Quarter and Full Year 2025 Results
Globe Newswire (Thu, 26-Feb 6:10 AM ET)
Enovis Corp is a medical technology manufacturer and distributor of medical devices used in reconstructive surgery, rehabilitation, pain management, and physical therapy. Its products support patient care from injury prevention through post-surgical or post-injury rehabilitation and treatment of degenerative conditions. The company's reportable segments include Prevention & Recovery and Reconstructive segments. The majority of revenueis derived from the Prevention & Recovery segment, which includes products that are used by orthopedic specialists, primary care physicians, physical therapists, chiropractors, athletic trainers and other healthcare professionals to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformitiesand sports-related injuries.
Enovis trades on the NYSE stock market under the symbol ENOV.
As of May 12, 2026, ENOV stock price climbed to $25.99 with 2,321,993 million shares trading.
ENOV has a beta of 2.38, meaning it tends to be more sensitive to market movements. ENOV has a correlation of 0.31 to the broad based SPY ETF.
ENOV has a market cap of $1.50 billion. This is considered a Small Cap stock.
Last quarter Enovis reported $589 million in Revenue and $.89 earnings per share. This beat revenue expectation by $18 million and exceeded earnings estimates by $.08.
In the last 3 years, ENOV traded as high as $66.14 and as low as $21.00.
The top ETF exchange traded funds that ENOV belongs to (by Net Assets): IJR, VTI, IWM, VB, VBR.
ENOV has underperformed the market in the last year with a return of -21.4%, while SPY returned +32.1%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in ENOV shares. However, ENOV has outperformed the market in the last 3 month and 2 week periods, returning +14.0% and +5.9%, while SPY returned +6.9% and +3.2%, respectively. This indicates ENOV has been having a stronger performance recently.
ENOV support price is $23.91 and resistance is $25.65 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ENOV shares will trade within this expected range on the day.